BC
ICPT

Bridgefront Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bridgefront Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,053
Closed -$209K – 974
2021
Q1 		$209K Buy
+9,053
New +$252K 0.07% 572

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bridgefront Capital's ICPT Position: Q2 2021 in Review

Bridgefront Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 9,053 shares — an estimated $209K sold.

Bridgefront Capital first reported a position in ICPT in Q1 2021 and held it in 1 quarter. The position peaked at $209K in Q1 2021. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Bridgefront Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bridgefront Capital sold 9,053 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $209K.
  • Bridgefront Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Bridgefront Capital's Intercept Pharmaceuticals, Inc. position peaked at $209K in Q1 2021.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.